<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d370" origId="Carbidopa"><sentence id="DrugDDI.d370.s0" origId="s0" text="Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products."><entity id="DrugDDI.d370.s0.e0" origId="s0.p5" charOffset="47-52" type="drug" text="drugs"/><entity id="DrugDDI.d370.s0.e1" origId="s0.p9" charOffset="89-96" type="drug" text="LODOSYN"/><entity id="DrugDDI.d370.s0.e2" origId="s0.p11" charOffset="98-107" type="drug" text="Carbidopa"/><entity id="DrugDDI.d370.s0.e3" origId="s0.p14" charOffset="120-128" type="drug" text="levodopa"/><entity id="DrugDDI.d370.s0.e4" origId="s0.p16" charOffset="132-150" type="drug" text="carbidopa-levodopa"/><pair id="DrugDDI.d370.s0.p0" e1="DrugDDI.d370.s0.e0" e2="DrugDDI.d370.s0.e1" interaction="true"/><pair id="DrugDDI.d370.s0.p1" e1="DrugDDI.d370.s0.e0" e2="DrugDDI.d370.s0.e2" interaction="false"/><pair id="DrugDDI.d370.s0.p2" e1="DrugDDI.d370.s0.e0" e2="DrugDDI.d370.s0.e3" interaction="true"/><pair id="DrugDDI.d370.s0.p3" e1="DrugDDI.d370.s0.e0" e2="DrugDDI.d370.s0.e4" interaction="false"/><pair id="DrugDDI.d370.s0.p4" e1="DrugDDI.d370.s0.e1" e2="DrugDDI.d370.s0.e2" interaction="false"/><pair id="DrugDDI.d370.s0.p5" e1="DrugDDI.d370.s0.e1" e2="DrugDDI.d370.s0.e3" interaction="false"/><pair id="DrugDDI.d370.s0.p6" e1="DrugDDI.d370.s0.e1" e2="DrugDDI.d370.s0.e4" interaction="false"/><pair id="DrugDDI.d370.s0.p7" e1="DrugDDI.d370.s0.e2" e2="DrugDDI.d370.s0.e3" interaction="false"/><pair id="DrugDDI.d370.s0.p8" e1="DrugDDI.d370.s0.e2" e2="DrugDDI.d370.s0.e4" interaction="false"/><pair id="DrugDDI.d370.s0.p9" e1="DrugDDI.d370.s0.e3" e2="DrugDDI.d370.s0.e4" interaction="false"/></sentence><sentence id="DrugDDI.d370.s1" origId="s1" text="Symptomatic postural hypotension has occurred when LODOSYN, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs."><entity id="DrugDDI.d370.s1.e0" origId="s1.p21" charOffset="51-58" type="drug" text="LODOSYN"/><entity id="DrugDDI.d370.s1.e1" origId="s1.p23" charOffset="71-79" type="drug" text="levodopa"/><entity id="DrugDDI.d370.s1.e2" origId="s1.p25" charOffset="83-101" type="drug" text="carbidopa-levodopa"/><entity id="DrugDDI.d370.s1.e3" origId="s1.p31" charOffset="174-196" type="drug" text="antihypertensive drugs"/><pair id="DrugDDI.d370.s1.p0" e1="DrugDDI.d370.s1.e0" e2="DrugDDI.d370.s1.e1" interaction="false"/><pair id="DrugDDI.d370.s1.p1" e1="DrugDDI.d370.s1.e0" e2="DrugDDI.d370.s1.e2" interaction="false"/><pair id="DrugDDI.d370.s1.p2" e1="DrugDDI.d370.s1.e0" e2="DrugDDI.d370.s1.e3" interaction="true"/><pair id="DrugDDI.d370.s1.p3" e1="DrugDDI.d370.s1.e1" e2="DrugDDI.d370.s1.e2" interaction="false"/><pair id="DrugDDI.d370.s1.p4" e1="DrugDDI.d370.s1.e1" e2="DrugDDI.d370.s1.e3" interaction="false"/><pair id="DrugDDI.d370.s1.p5" e1="DrugDDI.d370.s1.e2" e2="DrugDDI.d370.s1.e3" interaction="true"/></sentence><sentence id="DrugDDI.d370.s2" origId="s2" text="Therefore, when therapy with LODOSYN, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required."><entity id="DrugDDI.d370.s2.e0" origId="s2.p35" charOffset="29-36" type="drug" text="LODOSYN"/><entity id="DrugDDI.d370.s2.e1" origId="s2.p39" charOffset="60-68" type="drug" text="levodopa"/><entity id="DrugDDI.d370.s2.e2" origId="s2.p41" charOffset="72-90" type="drug" text="carbidopa-levodopa"/><entity id="DrugDDI.d370.s2.e3" origId="s2.p46" charOffset="150-171" type="drug" text="antihypertensive drug"/><pair id="DrugDDI.d370.s2.p0" e1="DrugDDI.d370.s2.e0" e2="DrugDDI.d370.s2.e1" interaction="false"/><pair id="DrugDDI.d370.s2.p1" e1="DrugDDI.d370.s2.e0" e2="DrugDDI.d370.s2.e2" interaction="false"/><pair id="DrugDDI.d370.s2.p2" e1="DrugDDI.d370.s2.e0" e2="DrugDDI.d370.s2.e3" interaction="true"/><pair id="DrugDDI.d370.s2.p3" e1="DrugDDI.d370.s2.e1" e2="DrugDDI.d370.s2.e2" interaction="false"/><pair id="DrugDDI.d370.s2.p4" e1="DrugDDI.d370.s2.e1" e2="DrugDDI.d370.s2.e3" interaction="false"/><pair id="DrugDDI.d370.s2.p5" e1="DrugDDI.d370.s2.e2" e2="DrugDDI.d370.s2.e3" interaction="true"/></sentence><sentence id="DrugDDI.d370.s3" origId="s3" text="For patients receiving monoamine oxidase inhibitors, see CONTRAINDICATIONS."><entity id="DrugDDI.d370.s3.e0" origId="s3.p52" charOffset="23-51" type="drug" text="monoamine oxidase inhibitors"/></sentence><sentence id="DrugDDI.d370.s4" origId="s4" text="Concomitant therapy with selegiline and carbidopa-levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone."><entity id="DrugDDI.d370.s4.e0" origId="s4.p56" charOffset="25-35" type="drug" text="selegiline"/><entity id="DrugDDI.d370.s4.e1" origId="s4.p58" charOffset="40-58" type="drug" text="carbidopa-levodopa"/><entity id="DrugDDI.d370.s4.e2" origId="s4.p64" charOffset="133-151" type="drug" text="carbidopa-levodopa"/><pair id="DrugDDI.d370.s4.p0" e1="DrugDDI.d370.s4.e0" e2="DrugDDI.d370.s4.e1" interaction="true"/><pair id="DrugDDI.d370.s4.p1" e1="DrugDDI.d370.s4.e0" e2="DrugDDI.d370.s4.e2" interaction="false"/><pair id="DrugDDI.d370.s4.p2" e1="DrugDDI.d370.s4.e1" e2="DrugDDI.d370.s4.e2" interaction="false"/></sentence><sentence id="DrugDDI.d370.s5" origId="s5" text="There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations."><entity id="DrugDDI.d370.s5.e0" origId="s5.p76" charOffset="128-153" type="drug" text="tricyclic antidepressants"/><entity id="DrugDDI.d370.s5.e1" origId="s5.p78" charOffset="158-189" type="drug" text="carbidopa-levodopa preparations"/><pair id="DrugDDI.d370.s5.p0" e1="DrugDDI.d370.s5.e0" e2="DrugDDI.d370.s5.e1" interaction="true"/></sentence><sentence id="DrugDDI.d370.s6" origId="s6" text="Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa."><entity id="DrugDDI.d370.s6.e0" origId="s6.p79" charOffset="0-32" type="drug" text="dopamine d2 receptor antagonists"/><entity id="DrugDDI.d370.s6.e1" origId="s6.p82" charOffset="40-54" type="drug" text="phenothiazines"/><entity id="DrugDDI.d370.s6.e2" origId="s6.p83" charOffset="56-70" type="drug" text="butyrophenones"/><entity id="DrugDDI.d370.s6.e3" origId="s6.p84" charOffset="72-83" type="drug" text="risperidone"/><entity id="DrugDDI.d370.s6.e4" origId="s6.p87" charOffset="89-98" type="drug" text="isoniazid"/><entity id="DrugDDI.d370.s6.e5" origId="s6.p91" charOffset="137-145" type="drug" text="levodopa"/><pair id="DrugDDI.d370.s6.p0" e1="DrugDDI.d370.s6.e0" e2="DrugDDI.d370.s6.e1" interaction="false"/><pair id="DrugDDI.d370.s6.p1" e1="DrugDDI.d370.s6.e0" e2="DrugDDI.d370.s6.e2" interaction="false"/><pair id="DrugDDI.d370.s6.p2" e1="DrugDDI.d370.s6.e0" e2="DrugDDI.d370.s6.e3" interaction="false"/><pair id="DrugDDI.d370.s6.p3" e1="DrugDDI.d370.s6.e0" e2="DrugDDI.d370.s6.e4" interaction="false"/><pair id="DrugDDI.d370.s6.p4" e1="DrugDDI.d370.s6.e0" e2="DrugDDI.d370.s6.e5" interaction="true"/><pair id="DrugDDI.d370.s6.p5" e1="DrugDDI.d370.s6.e1" e2="DrugDDI.d370.s6.e2" interaction="false"/><pair id="DrugDDI.d370.s6.p6" e1="DrugDDI.d370.s6.e1" e2="DrugDDI.d370.s6.e3" interaction="false"/><pair id="DrugDDI.d370.s6.p7" e1="DrugDDI.d370.s6.e1" e2="DrugDDI.d370.s6.e4" interaction="false"/><pair id="DrugDDI.d370.s6.p8" e1="DrugDDI.d370.s6.e1" e2="DrugDDI.d370.s6.e5" interaction="true"/><pair id="DrugDDI.d370.s6.p9" e1="DrugDDI.d370.s6.e2" e2="DrugDDI.d370.s6.e3" interaction="false"/><pair id="DrugDDI.d370.s6.p10" e1="DrugDDI.d370.s6.e2" e2="DrugDDI.d370.s6.e4" interaction="false"/><pair id="DrugDDI.d370.s6.p11" e1="DrugDDI.d370.s6.e2" e2="DrugDDI.d370.s6.e5" interaction="true"/><pair id="DrugDDI.d370.s6.p12" e1="DrugDDI.d370.s6.e3" e2="DrugDDI.d370.s6.e4" interaction="false"/><pair id="DrugDDI.d370.s6.p13" e1="DrugDDI.d370.s6.e3" e2="DrugDDI.d370.s6.e5" interaction="true"/><pair id="DrugDDI.d370.s6.p14" e1="DrugDDI.d370.s6.e4" e2="DrugDDI.d370.s6.e5" interaction="true"/></sentence><sentence id="DrugDDI.d370.s7" origId="s7" text="In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine."><entity id="DrugDDI.d370.s7.e0" origId="s7.p94" charOffset="39-47" type="drug" text="levodopa"/><entity id="DrugDDI.d370.s7.e1" origId="s7.p102" charOffset="107-116" type="drug" text="phenytoin"/><entity id="DrugDDI.d370.s7.e2" origId="s7.p104" charOffset="121-131" type="drug" text="papaverine"/><pair id="DrugDDI.d370.s7.p0" e1="DrugDDI.d370.s7.e0" e2="DrugDDI.d370.s7.e1" interaction="true"/><pair id="DrugDDI.d370.s7.p1" e1="DrugDDI.d370.s7.e0" e2="DrugDDI.d370.s7.e2" interaction="false"/><pair id="DrugDDI.d370.s7.p2" e1="DrugDDI.d370.s7.e1" e2="DrugDDI.d370.s7.e2" interaction="false"/></sentence><sentence id="DrugDDI.d370.s8" origId="s8" text="Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response."><entity id="DrugDDI.d370.s8.e0" origId="s8.p107" charOffset="22-27" type="drug" text="drugs"/><entity id="DrugDDI.d370.s8.e1" origId="s8.p108" charOffset="33-40" type="drug" text="LODOSYN"/><entity id="DrugDDI.d370.s8.e2" origId="s8.p110" charOffset="45-53" type="drug" text="levodopa"/><entity id="DrugDDI.d370.s8.e3" origId="s8.p112" charOffset="57-75" type="drug" text="carbidopa-levodopa"/><pair id="DrugDDI.d370.s8.p0" e1="DrugDDI.d370.s8.e0" e2="DrugDDI.d370.s8.e1" interaction="true"/><pair id="DrugDDI.d370.s8.p1" e1="DrugDDI.d370.s8.e0" e2="DrugDDI.d370.s8.e2" interaction="false"/><pair id="DrugDDI.d370.s8.p2" e1="DrugDDI.d370.s8.e0" e2="DrugDDI.d370.s8.e3" interaction="true"/><pair id="DrugDDI.d370.s8.p3" e1="DrugDDI.d370.s8.e1" e2="DrugDDI.d370.s8.e2" interaction="false"/><pair id="DrugDDI.d370.s8.p4" e1="DrugDDI.d370.s8.e1" e2="DrugDDI.d370.s8.e3" interaction="false"/><pair id="DrugDDI.d370.s8.p5" e1="DrugDDI.d370.s8.e2" e2="DrugDDI.d370.s8.e3" interaction="false"/></sentence><sentence id="DrugDDI.d370.s9" origId="s9" text="Iron salts may reduce the bioavailability of carbidopa and levodopa."><entity id="DrugDDI.d370.s9.e0" origId="s9.p123" charOffset="45-54" type="drug" text="carbidopa"/><entity id="DrugDDI.d370.s9.e1" origId="s9.p125" charOffset="59-67" type="drug" text="levodopa"/><pair id="DrugDDI.d370.s9.p0" e1="DrugDDI.d370.s9.e0" e2="DrugDDI.d370.s9.e1" interaction="false"/></sentence><sentence id="DrugDDI.d370.s10" origId="s10" text="The clinical relevance is unclear."/><sentence id="DrugDDI.d370.s11" origId="s11" text="Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties."><entity id="DrugDDI.d370.s11.e0" origId="s11.p130" charOffset="9-23" type="drug" text="metoclopramide"/><entity id="DrugDDI.d370.s11.e1" origId="s11.p134" charOffset="60-68" type="drug" text="levodopa"/><entity id="DrugDDI.d370.s11.e2" origId="s11.p136" charOffset="101-115" type="drug" text="metoclopramide"/><entity id="DrugDDI.d370.s11.e3" origId="s11.p141" charOffset="165-196" type="drug" text="dopamine receptor antagonistic"/><pair id="DrugDDI.d370.s11.p0" e1="DrugDDI.d370.s11.e0" e2="DrugDDI.d370.s11.e1" interaction="true"/><pair id="DrugDDI.d370.s11.p1" e1="DrugDDI.d370.s11.e0" e2="DrugDDI.d370.s11.e2" interaction="false"/><pair id="DrugDDI.d370.s11.p2" e1="DrugDDI.d370.s11.e0" e2="DrugDDI.d370.s11.e3" interaction="false"/><pair id="DrugDDI.d370.s11.p3" e1="DrugDDI.d370.s11.e1" e2="DrugDDI.d370.s11.e2" interaction="false"/><pair id="DrugDDI.d370.s11.p4" e1="DrugDDI.d370.s11.e1" e2="DrugDDI.d370.s11.e3" interaction="false"/><pair id="DrugDDI.d370.s11.p5" e1="DrugDDI.d370.s11.e2" e2="DrugDDI.d370.s11.e3" interaction="true"/></sentence></document>